{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:34:41Z","timestamp":1791999281827,"version":"4.4.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The rVSVDG-ZEBOV-GP (Ervebo\u00ae) vaccine is both immunogenic and protective against Ebola. However, the vaccine can cause a broad range of transient adverse reactions, from headache to arthritis. Identifying baseline reactogenicity signatures can advance personalized vaccinology and increase our understanding of the molecular factors associated with such adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we developed a machine learning approach to integrate prevaccination gene expression data with adverse events that occurred within 14 days post-vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and Discussion<\/jats:title><jats:p>We analyzed the expression of 144 genes across 343 blood samples collected from participants of 4 phase I clinical trial cohorts: Switzerland, USA, Gabon, and Kenya. Our machine learning approach revealed 22 key genes associated with adverse events such as local reactions, fatigue, headache, myalgia, fever, chills, arthralgia, nausea, and arthritis, providing insights into potential biological mechanisms linked to vaccine reactogenicity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1259197","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:14:26Z","timestamp":1699546466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts"],"prefix":"10.3389","volume":"14","author":[{"given":"Patr\u00edcia Concei\u00e7\u00e3o","family":"Gonzalez Dias Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Dominguez Crespo Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Yukio","family":"Mano Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Franco","family":"Moscardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula Barbosa","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 G.","family":"Costa-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Harandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle C.","family":"Haks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H. M.","family":"Ottenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Martinez-Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire-Anne","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Medaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helder I.","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.micinf.2014.11.007","article-title":"Ebola virus disease: a highly fatal infectious disease reemerging in West Africa","volume":"17","author":"To","year":"2015","journal-title":"Microbes Infect"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12099","article-title":"Immunity to viruses: learning from successful human vaccines","volume":"255","author":"Pulendran","year":"2013","journal-title":"Immunol Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.6.2730-2738.2002","article-title":"High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses","volume":"76","author":"Haglund","year":"2002","journal-title":"J Virol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41541-022-00508-7","article-title":"Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2","volume":"7","author":"Taddeo","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy565","article-title":"Detectable vesicular stomatitis virus (VSV)-specific humoral and cellular immune responses following VSV-ebola virus vaccination in humans","volume":"219","author":"Poetsch","year":"2019","journal-title":"J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/fmb-2019-0237","article-title":"Safety, immunogenicity and risk-benefit analysis of rVSV-\u0394G-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions","volume":"15","author":"Bache","year":"2020","journal-title":"Future Microbiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u2206G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.57","article-title":"The first steps towards the era of personalised vaccinology: predicting adverse reactions","volume":"15","author":"Pellegrino","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2014.03.031","article-title":"Global analyses of human immune variation reveal baseline predictors of postvaccination responses","volume":"157","author":"Tsang","year":"2014","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aal4656","article-title":"Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses","volume":"2","year":"2017","journal-title":"Sci Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.001","article-title":"Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders","volume":"36","author":"Bartholomeus","year":"2018","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1741-7015-11-184","article-title":"Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data","volume":"11","author":"Warimwe","year":"2013","journal-title":"BMC Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20209888","article-title":"Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine","volume":"16","author":"O\u2019Connor","year":"2020","journal-title":"Mol Syst Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001643","article-title":"Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes","volume":"20","author":"Syenina","year":"2022","journal-title":"PloS Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.054","article-title":"Focused human gene expression profiling using dual-color reverse transcriptase multiplex ligation-dependent probe amplification","volume":"33","author":"Haks","year":"2015","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00235-4","article-title":"Transcriptomic signatures induced by the Ebola virus vaccine rVSV\u0394G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study","volume":"3","author":"Vianello","year":"2022","journal-title":"Lancet Microbe"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1609\/icwsm.v3i1.13937","article-title":"Gephi: an open source software for exploring and manipulating networks","volume":"3","author":"Bastian","year":"2009","journal-title":"Third Int AAAI Conf Weblogs Soc Media"},{"key":"B28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75429","article-title":"Immune activation alters cellular and humoral responses to yellow fever 17D vaccine","volume":"124","author":"Muyanja","year":"2014","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.46149","article-title":"Identification of potential biomarkers of vaccine inflammation in mice","volume":"8","author":"McKay","year":"2019","journal-title":"eLife"},{"key":"B32","doi-asserted-by":"publisher","first-page":"P172","DOI":"10.1186\/2051-1426-2-S3-P172","article-title":"Self-adjuvanted RNActive\u00ae vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans","volume":"2","author":"Kowalczyk","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126054","article-title":"Immunomodulatory activity of humanized anti\u2013IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes","volume":"4","author":"Herold","year":"2019","journal-title":"JCI Insight"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13748","article-title":"Anti-IL-7 receptor \u03b1 monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study","volume":"85","author":"Ellis","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2015.123711","article-title":"Resimmune, an anti-CD3\u03f5 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma","volume":"100","author":"Frankel","year":"2015","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.12.007","article-title":"T cells as guardians of pain resolution","volume":"27","author":"Kavelaars","year":"2021","journal-title":"Trends Mol Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00768","article-title":"The role of T lymphocytes in skeletal muscle repair from traumatic and contraction-induced injury","volume":"9","author":"Deyhle","year":"2018","journal-title":"Front Physiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1259197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:14:31Z","timestamp":1699546471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1259197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2023.1259197"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1259197","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"article-number":"1259197"}}